1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline

BACKGROUND: CSE, a novel combination of Ceftriaxone, Sulbactam and Disodium EDTA (Class 1 Antibiotic Resistance Breaker), is being developed for the treatment of patients with serious Gram-negative infections and has completed a Phase-3 clinical trial (NCT03477422) for treatment of complicated urina...

Descripción completa

Detalles Bibliográficos
Autores principales: Mir, Mohd Amin, Chaudhary, Saransh, Mammen, Kim Jacob, Sood, Rajeev, Dogra, P N, Chadha, Sudhir, Mavuduru, Ravimohan, Sinha, Rahul Janak, Chaudhary, Manu, Shiekh, Gazalla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252982/
http://dx.doi.org/10.1093/ofid/ofy210.1615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252982/
http://dx.doi.org/10.1093/ofid/ofy210.1615

Ejemplares similares